NEWS RELEASE

Targeted Number of Subjects Registered for
Cardiovascular Patch Clinical Trial
Tokyo, Japan, January 27, 2021 --- Osaka Medical College, Fukui Tateami Co., Ltd.
and Teijin Limited announced today that they have completed their registration ofregistered their targeted number of subjects for an ongoing clinical trial of the OFT-G1(provisional name) patch for cardiovascular surgery. Participants, who are targeted forparticipation in a clinical trial that has been under way since May 2019, are patients ranging
from infants to adults who are suffering from various congenital heart diseases.
Osaka Medical College, Fukui Tateami and Teijin aim to apply for approval to manufacture
and market their cardiovascular patch after evaluating safety and efficacy data covering theone-year periods after each subject undergoes surgery using the OFT-G1 patch.
The OFT-G1 features a revolutionary design incorporating the Osaka Medical College’s
expertise in cardiovascular surgery, Fukui Tateami’s pioneering warp-knitting technology
and Teijin’s advanced polymer-application technology. Development was supported bya special program launched in 2017 by the Japan Agency for Medical Research andDevelopment (AMED) to facilitate collaboration between medical academia and industry.
Also, in April 2018, the Ministry of Health, Labor and Welfare designated the OFT-G1 as
a “SAKIGAKE” product qualifying for various incentives to speed up its approval forclinical use.
Treatments have been devised to improve the long-term survival of patients who
undergo cardiovascular surgeries for purposes such as replacing defective heart tissue
or enlarging narrowed blood vessels (stenosis). Demands are growing for increasingly
advanced treatments that are less likely to cause stenosis due to the patient’s somatic(physical) growth in areas where patches have been implanted and reoperations due topatch deterioration or calcification after long-term implantation.
The OFT-G1’s absorbable portion is naturally replaced with the patients’ own tissue
after implantation. Also, its strong but expandable structure allows it to conform to thepatient’s somatic growth. Accordingly, the OFT-G1 is expected to alleviate physical,
mental or financial burdens that patients and their families may experience in regard topossible corrective surgeries.
Going forward, Osaka Medical College, Fukui Tateami and Teijin will continue withclinical trials to confirm the clinical effectiveness and safety of the OFT-G1
cardiovascular patch, and thereafter work toward approval as quickly as possible inJapan and then other countries worldwide. Simultaneously, they will continue with

product development efforts aimed at enhancing the quality of life for patients withcardiovascular diseases.
About Osaka Medical College
Established in 1927 as Japan’s first five-year higher school of medicine, Osaka Medical
College celebrated its 90th anniversary in 2017 having produced more than 9,000
skilled physicians. The College’s nursing education program has a similar history, andhas trained more than 4,500 nurses. Furthermore, the College will form a promising
merger with Osaka University of Pharmaceutical Sciences this year to strengthen theirpotential.
URL: https://www.osaka-med.ac.jp/en/
Press Contact
Section of Promoting Academia-Industry-Government Cooperation
Research & Development Center
Osaka Medical College+81 72 684 7141
sangakukan@osaka-med.ac.jp
About Fukui Tateami Co., Ltd.
Fukui Tateami is a warp knitted fabric manufacturing company located in Fukui, Japan,with 90 employees and more. Our products encompass a wide spectrum of applications,such as fashionable apparel, active sportswear, automotive interiors, industrial
materials, household textiles. With over 75 years of extensive experience and advanced
technology, Fukui Tateami has entered the medical field. It posted sales of JPY3.4billion (USD 31 million) and total assets of JPY 3.0 billion (USD 27 million) in the fiscal
year ending March 31, 2019.
Please visit http://www.fukutate.co.jp/enPress ContactGeneral Affairs
Fukui Tateami Co., Ltd.
+81 776 54 3602
info@fukutate.co.jp
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare

equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company that
supports the society of the future. The group comprises more than 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2020.
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp